section name header

Indications

REMS

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: chest pain, edema, hypertension.

Derm: ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS, DRUG RASH WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS, pruritus, purpura, rash, STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS.

EENT: epistaxis.

GI: abdominal pain, diarrhea, dyspepsia, gastritis, GI BLEEDING.

Hemat: BLEEDING, NEUTROPENIA, THROMBOTIC THROMBOCYTOPENIC PURPURA.

Metab: hypercholesterolemia.

MS: arthralgia, back pain.

Neuro: depression, dizziness, fatigue, headache.

Resp: cough, dyspnea, eosinophilic pneumonia.
Misc: fever, (INCLUDING ANAPHYLAXIS)HYPERSENSITIVITY REACTIONS .

Interactions

Drug-Drug:

Drug-Natural Products:

Availability

(Generic available)

Route/Dosage

Recent MI, Stroke, or Peripheral Arterial Disease

Acute Coronary Syndrome

US Brand Names

Plavix

Action

Therapeutic Effects:

Classifications

Therapeutic Classification: antiplatelet agents

Pharmacologic Classification: platelet aggregation inhibitors

Pharmacokinetics

Absorption: Well absorbed following oral administration; rapidly metabolized to an active antiplatelet compound. Parent drug has no antiplatelet activity.

Distribution: Unknown.

Protein Binding: Clopidogrel: 98%; active metabolite: 94%.

Metabolism/Excretion: Rapidly and extensively converted by the liver via the CYP2C19 isoenzyme to its active metabolite, which is then eliminated 50% in urine and 45% in feces;2% of Whites, 4% of Blacks, and 14% of Asians have CYP2C19 genotype that results in reduced metabolism of clopidogrel (poor metabolizers) into its active metabolite (may result in antiplatelet effects).

Half-life: 6 hr (active metabolite 30 min).

Time/Action Profile

(effects on platelet function)

ROUTEONSETPEAKDURATION
POwithin 24 hr3–7 days5 days

†Following discontinuation.

Patient/Family Teaching

Pronunciation

kloh-PID-oh-grel

Pill Image

clopidogrel_135_861.jpg